# Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

> **NCT02521285** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Barrett Esophagus
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Aspirin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02521285
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01-15
- **Primary completion:** 2019-06-18
- **Final completion:** 2027-03-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521285, "Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02521285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*